Journal Information
Vol. 36. Issue 2.
Pages 73-76 (February 2000)
Share
Share
Download PDF
More article options
Vol. 36. Issue 2.
Pages 73-76 (February 2000)
Full text access
Flujos inspiratorios máximos en niños sanos y asmáticos de 4 a 8 años. Implicaciones para la inhalación de medicamentos en polvo
Peak inspiratory flow in healthy and asthmatic children between 4 and 8 years of age: implications for inhalation of powdered medication
Visits
7810
P. Aguilar Miranda, J. Mallol Villablanca
Corresponding author
mri@lauca.usach.cl

Correspondencia: Clasificador 23 - Correo 9. Providencia. Santiago de Chile.
Departamento de Medicina Respiratoria Infantil. Facultad de Ciencias Médicas. Hospital El Pino. Servicio de Salud Metropolitano Sur. Universidad de Santiago de Chile (USACH)
This item has received
Article information

Veintidós niños asmáticos asintomáticos y 21 niños sanos, con edades comprendidas entre 4 y 8 años, fueron estudiados con el fin de determinar los flujos inspiratorios máximos (FIM) generados en condiciones basales y a través de un dispositivo de aerosol en polvo (TurbuhalerTM). Los FIM fueron medidos aleatoriamente, durante 3 días alternados, con un espirómetro computarizado. En los niños sanos, el rango de las medias de los valores de FIM basal (FIMB) y a través del TurbuhalerTM (FIMTH) fue de 129 a 244l/min y de 72 a 99l/min, respectivamente. En los asmáticos, dichos rangos fueron de 122 a 236l/min para FIMB y de 79 a 102l/min para FIMTH. El FIM estuvo directa y significativamente relacionado con la edad (p<0,05). La diferencia entre los FIMTH de asmáticos y sanos no fue significativa. Los FIM de niños chilenos, sanos y asmáticos, de 4 a 8 años están por encima de los valores requeridos para obtener un aerosol óptimo con este tipo de dispositivo. Este estudio sugiere que los aerosoles en polvo producidos por dispositivos como el empleado en este trabajo, podrían usarse en niños a partir de los 4 años de edad.

Palabras clave:
Flujo inspiratorio máximo
Aerosol en polvo
Niños

Twenty-two asymptomatic asthmatic children and twenty-one healthy controls aged between 4 and 8 years old were studied in order to determine peak inspiratory flow (PIF) in baseline conditions through a TurbuhalerTM powder aerosol device. PIF was measured randomly on one of three days using computerized spirometry. In healthy children, baseline PIF ranged from 129 to 244L/min; PIF through the TurbuhalerTM ranged from 72 to 99l/min. In asthmatics, the ranges were 122 to 236l/min and 79 to 102l/min for baseline and TurbuhalerTM PIF, respectively. PIF was significantly related to age (p<0.05). The difference between PIF through the TurbuhalerTM for asthmatic and healthy children was not significant. PIF of healthy and asthmatic Chilean children between 4 and 8 years of age exceeded the level required to obtain an optimum dose from this type of device. This study suggests that the aerosol powder doses produced by devices such as that used in this study can be used by children from age 4 and older.

Keywords:
Peak inspiratory flow
Powder aerosol
Children
Full text is only aviable in PDF
Bibliografía
[1.]
G. Persson, E. Gruvstad, E. Stahl.
A new multiple dose powder inhaler (Turbuhaler®), compared with a pressurized inhaler in a study of terbutaline in asthmatics.
Eur Respir J, 1 (1988), pp. 681-684
[2.]
S. Pedersen.
Inhalers and neubulizers: which to choose and why.
Respir Med, 90 (1996), pp. 69-77
[3.]
S.P. Newman.
Metered dose pressurized aerosols and the ozone layer.
Eur Respir J, 3 (1990), pp. 495-497
[4.]
C.R. Johnsen, E.R. Weeke.
Turbuhaler®: a new device for dry powder terbutaline inhalation.
Allergy, 43 (1988), pp. 392-395
[5.]
C.G. Löfdahl, L. Anderson, E. Bondesson, L.G. Carlsson, K. Friberg, J. Hedner, et al.
Eur Respir J, 10 (1997), pp. 2474-2478
[6.]
A.C. Raimondi, J. Schottlender, D. Lombardi, N.A. Molfino.
Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder.
Chest, 112 (1997), pp. 24-28
[7.]
J.H. Toogood, F.A. White, J.C. Baskerville, L.J. Fraher, B. Jennings.
Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler.
J Allergy Clin Immunol, 99 (1997), pp. 186-193
[8.]
K.G. Nielsen, M. Skov, B. Klug, M. Ifversen, H. Bisgaard.
Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer ®.
Eur Respir J, 10 (1997), pp. 2105-2109
[9.]
L. Borgstöm, E. Bondesson, F. Morén, E. Trofast, S.P. Newman.
Lung deposition of budesonide inhaled via Turbuhaler®: a comparison with terbutaline suplhate in normal subjects.
Eur Respir J, 7 (1994), pp. 69-73
[10.]
R. Richards, C.R. Dickson, G. Renwick, R.A. Lewis, S.T. Holgate.
Absortion and disposition kinetics of cromolyn sodium and the influence of inhalation technique.
J Pharmacol Exp Ther, 241 (1987), pp. 1028-1031
[11.]
S. Pedersen, O.R. Hansen, G. Fuglsang.
Influence of inspiratory flow rate upon the effect of a Turbuhaler.
Arch Dis Child, 65 (1990), pp. 308-319
[12.]
K.H.K. Hsu, D.E. Jenkins, G.P. Hsi, E. Bourhofer, V. Thompson, N. Tanaka, et al.
Ventilatory functions on normal children and young adults Mexican-American white and black. Spirometry.
J Pediatr, 95 (1979), pp. 14-23
[13.]
J.O. Warner, C.K. Naspitz.
Third International Pediatric Consensus Statement on the Management of Childhood Asthma.
Pediatr Pulmonol, 25 (1998), pp. 1-17
[14.]
P.H. Quanjer, G.J. Tammeling, J.E. Cotes, O.F. Pedersen, R. Peslin, J.C. Yernault.
Lung volumes and forced ventilatory flows Official of the European Respiratory Society.
Eur Respir J, 6 (1993), pp. 5-83
[15.]
D.L. Ross, R.K. Schultz.
Effect of inhalation flow rate on the dosing characteristics of dry powder inhaled and metered dose inhaler products.
J Aerosol Med, 9 (1996), pp. 215-226
[16.]
E. Ståhl, L.B. Ribeiro, G. Sandahl.
Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbohaler® in children with mild to moderate asthma.
[17.]
A.F. Isles, C.J.L. Newth, Management of acute asthma in children.
Clinical Paediatrics: asthma, pp. 741-748
[18.]
D. Ganderton.
General factors influencing drug delivery to the lung.
Respir Med, 91 (1997), pp. 13-16
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?